Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...

In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new ...

The European Commission has pulled marketing authorisations for generic versions of Biogen’s oral multiple sclerosis therapy Tecfidera, after concluding that the brand qualifies for additional ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure ...

Sales of Biogen’s MS drugs like Tecfidera and Tysabri are likely to have declined amid rising competitive pressure in the market. Tecfidera sales have been declining as multiple generic versions ...